Press Releases :: Kazia Therapeutics (KZIA)

Mar 1, 2021 10:00 am EST Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

Dec 10, 2020 10:00 am EST Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG

Dec 9, 2020 10:30 am EST Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

Nov 17, 2020 5:47 pm EST Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

Oct 16, 2020 10:30 am EDT Kazia Executes Agreement To Commence GBM Agile Pivotal Study

Sep 22, 2020 10:00 am EDT Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

Aug 24, 2020 5:30 am EDT US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

Aug 23, 2020 9:03 pm EDT US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

Aug 20, 2020 10:30 am EDT US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

Aug 7, 2020 10:30 am EDT US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG